Pfizer has wrapped up the sale of its Capsugel drug-delivery unit to the investment firm KKR for $2.3 billion in cash. Capsugel offers a variety of products, including liquid formulations as part of its Licaps drug delivery system. It's part of an effort by Pfizer to "make the company smaller." Pharmaceutical Business Review reports that Capsugel will keep a corporate presence with headquarters in New Jersey. Story | Release | Background